Nektar Therapeutics (NKTR) – Investment Analysts’ Weekly Ratings Changes

Nektar Therapeutics (NASDAQ: NKTR) has recently received a number of price target changes and ratings updates:

• 4/22/2026 – Nektar Therapeutics had its “buy” rating reaffirmed by Jefferies Financial Group Inc..
• 4/21/2026 – Nektar Therapeutics had its price target raised by Citigroup Inc. from $123.00 to $151.00. They now have a “buy” rating on the stock.
• 4/21/2026 – Nektar Therapeutics had its price target raised by Wedbush from $70.00 to $95.00. They now have a “neutral” rating on the stock.
• 4/20/2026 – Nektar Therapeutics had its price target raised by BTIG Research from $151.00 to $178.00. They now have a “buy” rating on the stock.
• 4/20/2026 – Nektar Therapeutics had its price target raised by HC Wainwright from $165.00 to $185.00. They now have a “buy” rating on the stock.
• 4/11/2026 – Nektar Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/29/2026 – Nektar Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/24/2026 – Nektar Therapeutics is now covered by Wedbush. They set a “neutral” rating and a $70.00 price target on the stock.
• 3/21/2026 – Nektar Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/17/2026 – Nektar Therapeutics is now covered by TD Cowen. They set a “buy” rating on the stock.
• 3/16/2026 – Nektar Therapeutics had its price target raised by Citigroup Inc. from $102.00 to $123.00. They now have a “buy” rating on the stock.
• 3/13/2026 – Nektar Therapeutics had its “outperform” rating reaffirmed by Oppenheimer Holdings, Inc.. They now have a $140.00 price target on the stock.

Insider Activity at Nektar Therapeutics

In related news, CEO Howard W. Robin sold 423 shares of Nektar Therapeutics stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $73.00, for a total transaction of $30,879.00. Following the transaction, the chief executive officer owned 75,489 shares in the company, valued at approximately $5,510,697. The trade was a 0.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 3.71% of the company’s stock.

Nektar Therapeutics (NASDAQ:NKTR) is a biopharmaceutical company dedicated to discovering and developing novel drug candidates through its proprietary chemistry and immunology platforms. The company focuses on polymer conjugate technology, which enables the creation of longer-acting versions of existing drugs, and on T-cell modulatory therapies aimed at harnessing the body’s immune system to treat cancer and other serious diseases.

Nektar’s product portfolio and pipeline include a range of clinical-stage and partnered programs.